Insider Selling: Aduro BioTech Inc (ADRO) Insider Sells $356,400.00 in Stock

Aduro BioTech Inc (NASDAQ:ADRO) insider Stephen T. Isaacs sold 40,000 shares of the firm’s stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $8.91, for a total value of $356,400.00. Following the transaction, the insider now owns 245,746 shares in the company, valued at $2,189,596.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of NASDAQ ADRO opened at $8.05 on Friday. Aduro BioTech Inc has a 12-month low of $5.82 and a 12-month high of $14.05.

How to Become a New Pot Stock Millionaire

Aduro BioTech (NASDAQ:ADRO) last announced its earnings results on Thursday, March 1st. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. The business had revenue of $3.76 million for the quarter, compared to analysts’ expectations of $4.32 million. Aduro BioTech had a negative return on equity of 37.86% and a negative net margin of 532.88%. research analysts predict that Aduro BioTech Inc will post -1.29 earnings per share for the current year.

Several research analysts have commented on the company. BidaskClub upgraded Aduro BioTech from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 29th. Oppenheimer reduced their price objective on Aduro BioTech from $15.00 to $13.00 and set an “outperform” rating on the stock in a report on Wednesday, December 13th. Zacks Investment Research downgraded Aduro BioTech from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. HC Wainwright reduced their price objective on Aduro BioTech from $18.00 to $9.50 and set a “buy” rating on the stock in a report on Wednesday, December 13th. Finally, Canaccord Genuity set a $30.00 price objective on Aduro BioTech and gave the stock a “buy” rating in a report on Thursday, December 14th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Aduro BioTech has a consensus rating of “Buy” and an average price target of $14.50.

A number of hedge funds and other institutional investors have recently made changes to their positions in ADRO. Bank of New York Mellon Corp boosted its position in Aduro BioTech by 23.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 175,642 shares of the biotechnology company’s stock valued at $1,871,000 after acquiring an additional 33,843 shares in the last quarter. SG Americas Securities LLC bought a new stake in Aduro BioTech during the 3rd quarter valued at $167,000. Trexquant Investment LP bought a new stake in Aduro BioTech during the 3rd quarter valued at $175,000. Wells Fargo & Company MN boosted its position in Aduro BioTech by 111.5% during the 3rd quarter. Wells Fargo & Company MN now owns 72,854 shares of the biotechnology company’s stock valued at $776,000 after acquiring an additional 38,415 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in Aduro BioTech by 5.5% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 174,478 shares of the biotechnology company’s stock valued at $1,859,000 after acquiring an additional 9,140 shares in the last quarter. 44.94% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Aduro BioTech Inc (ADRO) Insider Sells $356,400.00 in Stock” was published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3337575/insider-selling-aduro-biotech-inc-adro-insider-sells-356400-00-in-stock.html.

About Aduro BioTech

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Financial Survey: ARMO BioSciences  & The Competition
Financial Survey: ARMO BioSciences & The Competition
Head to Head Comparison: Trxade Group  and Its Competitors
Head to Head Comparison: Trxade Group and Its Competitors
Sierra Bancorp  Expected to Post Earnings of $0.46 Per Share
Sierra Bancorp Expected to Post Earnings of $0.46 Per Share
Zacks: Analysts Anticipate Suncor Energy  Will Announce Earnings of $0.46 Per Share
Zacks: Analysts Anticipate Suncor Energy Will Announce Earnings of $0.46 Per Share
Boingo Wireless  CEO David Hagan Sells 59,500 Shares
Boingo Wireless CEO David Hagan Sells 59,500 Shares
NovoCure  Insider Sells $1,042,302.80 in Stock
NovoCure Insider Sells $1,042,302.80 in Stock


Leave a Reply

© 2006-2018 Ticker Report. Google+.